Genomate Health

06/18/2026

Most cancer treatment decisions are made with incomplete information.

Not because oncologists aren't skilled. But because cancer is genuinely complex; a single tumor can carry dozens of interacting molecular alterations, and making sense of all of them together, in real time, for each individual patient, is one of the hardest problems in modern medicine.

In this Labroots webinar, Dr. Istvan Petak explores why that interpretive gap exists and what it takes to close it.

The conversation covers how combinatorial molecular complexity creates bottlenecks in clinical decision-making, what distinguishes computational reasoning from conventional AI approaches, and how a systems-level understanding of cancer biology can support more personalized treatment decisions, for every patient, not just those at major research centers.

If you're an oncologist navigating complex cases, or a patient trying to understand why cancer decisions can feel uncertain even with good data, this one is worth your time.

Watch the full webinar: https://www.labroots.com/de/webinar/keynote-presentation-computational-reasoning-missing-layer-precision-oncology-w-live-q-a

06/16/2026

The moments that matter most are worth protecting.

This , we're reminded that men continue to face higher rates of preventable illness and premature mortality, including from cancers such as prostate, lung, and colorectal cancer.

While screening and early diagnosis remain critical, advances in precision oncology are helping healthcare teams better understand each patient's disease and make more informed treatment decisions based on the biology of their tumor.

Earlier understanding can lead to better-informed choices. And better-informed choices can help change outcomes.

For patients and families seeking additional clarity after a cancer diagnosis, Genomate Health's Second Opinion Service provides a comprehensive analysis of your tumor's complete molecular profile, helping identify personalized treatment options and supporting more confident decision-making alongside your care team. Learn more: https://lnkd.in/ddcPfrX8

06/12/2026

Can Genomate® help identify which therapies are most likely to benefit cancer patients in routine clinical practice?

At AI in Oncology 2026, Christophe Le Tourneau (Villejuif) will present results from a study of patients discussed by the Institut Curie Molecular Tumor Board, evaluating the clinical utility of computational reasoning in routine oncology practice.

The analysis found that patients receiving high-ranked therapies identified by Genomate experienced nearly double the median progression-free survival compared to those receiving low-ranked therapies (6.8 vs. 3.4 months). Overall survival more than doubled (16.6 vs. 7.8 months), while objective response rates increased from 8% to 33%. Importantly, the study also showed that not all targeted therapies deliver the same benefit. Therapies ranked highly by Genomate® outperformed chemotherapy, while low-ranked targeted therapies performed worse, highlighting the importance of matching treatments to the full molecular context of a patient's tumor.

Date: June 23, 2026 | 12:20–12:27 PM
Session: Reinventing Clinical Trials and Drug Discovery with AI
Authors: Barbara Vodicska, Eniko Kispeter, Dora Lakatos, Gabor Gyorgy Kalmar, Robert Doczi, Dora Gorog-Tihanyi, Anna Dirner, William T. Beck, Ivan Bièche, Edith Borcoman, Nicolas Servant, Kenza Nedara, Sarah Watson, Célia Dupain, Istvan Petak, Christophe Le Tourneau

06/10/2026

Too many cancer patients leave their appointments not knowing if they leave treatment options on the table.

Here's the reality: most tumors carry an average of 5 distinct genetic changes. Yet only around 7% of cancer patients today benefit from a therapy actually matched to their genomic profile. Not because the options aren't there, but because the complexity of interpreting all that data is beyond what any single clinician can manually assess in the time they have. And in cancer care, that gap can be life-altering.

Genomate® was built to close it.

Our Second Opinion Service combines physician oversight with computational reasoning technology to systematically analyze genomic findings, pathway interactions, treatment opportunities, and relevant clinical evidence. Every case undergoes multidisciplinary expert review, with findings and treatment considerations shared in a one-on-one telehealth consultation with a board-certified oncologist.

The goal is simple: to ensure every patient has access to the fullest possible understanding of their treatment opportunities before making critical care decisions.

Available now in 12 states, expanding nationwide. No travel. No waiting rooms. Eligible for HSA/FSA reimbursement.

Check your eligibility in under 30 seconds at: https://bit.ly/4vDg50L

Full press release: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/many-cancer-patients-leave-treatment-options-on-the-table-you-dont-ha-1174450

06/07/2026

No two cancers are the same.

Every tumor has its own biology. Every patient brings a unique clinical history, genetic profile, and treatment journey. What works for one person may not work for another.

By understanding the full molecular complexity of each patient’s disease, precision oncology can support more informed, individualized treatment decisions, helping clinicians identify therapies that are better aligned with the biology of the cancer.

Because every patient deserves a treatment strategy built around their cancer, not a one-size-fits-all approach.

This , we reaffirm our commitment to helping patients better understand their disease through precision oncology and independent second opinions when facing complex treatment decisions: https://bit.ly/3PMt0OS

06/04/2026

Precision oncology doesn't stop at sequencing.

As part of the BRECISE project, Genomate analyzed bladder cancer patient cohorts from Erasmus MC to identify targeted therapy candidates for ex vivo validation using our computational reasoning platform.

The goal: move beyond individual mutations and understand the complete molecular context of each tumor to uncover more precise treatment opportunities. A great example of how computational reasoning can help translate molecular complexity into actionable therapeutic insights.

Barbara Vodicska, PhD, shares more about this milestone and what's next for the project: https://www.youtube.com/watch?v=ulyagBSLnP8

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

06/02/2026

We can sequence tumors at scale.
But interpreting increasingly complex molecular profiles, often involving multiple driver alterations in most cases, remains a major challenge.

At , we’ve presented an analysis of 20,923 patients from the MSK-CHORD clinicogenomic dataset, exploring the clinical utility of Genomate®, our computational reasoning system.

Our findings showed:
• 75% of tumors were associated with at least one high-scored* molecularly targeted therapy option
• Yet only 37% of patients received such targeted therapy during the whole course of their treatment, and only 26.5% among patients right after the NGS testing
• Tumors contained an average of 4.6 driver alterations, highlighting the growing complexity of molecular decision-making

The results underscore an important reality in modern oncology: the challenge is no longer only generating genomic data, but interpreting the full molecular context to guide treatment decisions at scale.

Breakdown of the results here: https://lnkd.in/dn4qkq4a
Full abstract: https://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17086?presentation=263141

Dóra Lakatos PhD, Robert Doczi, PhD, Mária Kocsis-Steinbach, Kalmar Gabor, Anna Dirner, Enikő Kispéter, Dóra Görög-Tihanyi, Barbara Vodicska, PhD, William T Beck, Istvan Petak MD, PhD



* Previous research evidenced that MTAs assigned with a high Genomate score provide increased clinical benefit (NPJ Precis Oncol. 2021 5:59; NPJ Precis Oncol. 2025 9:159).

05/31/2026

Cancer care is full of difficult decisions.
What treatment is right?
What happens next?
Is there another option?
These are questions many patients are forced to face, often under pressure, often without certainty.

Prevention is different. Smoking is linked to up to 1 in 3 cancer deaths, making it one of the most preventable risk factors.

World No To***co Day is a reminder that some of the most important choices happen long before a diagnosis, when they can still change what comes next.
Because the best cancer decision is sometimes the one you never have to make.

***coDay

05/29/2026

Brain tumors are among the most complex cancers. Not just because of what they are, but because of where they are. A tumor’s location can limit treatment options. Its biology can change how it behaves. And even small differences can lead to very different outcomes.

That means every decision carries weight. And uncertainty is often part of the process.

At Genomate Health, we focus on understanding that complexity, looking beyond isolated findings to see how everything connects within a patient’s cancer.

Because when the full picture becomes clearer, so do the decisions: https://bit.ly/3RBiN8w

05/28/2026

Heading to ? Let’s meet!

Dóra Lakatos PhD, Head of Computational Science at Genomate Health, and Julia Deri, Precision Oncology Specialist at Oncompass Medicine, a Genomate Health company, will be there to present our latest research on computational reasoning and large-scale tumor genomic data.
If you’ll be at ASCO and would like to connect, let us know. We’re excited to meet clinicians, researchers, partners, and innovators who are thinking about the future of precision oncology, real-world evidence, and computational approaches to cancer care.

Our latest study explores how computational reasoning applied to large-scale real-world tumor genomic data may help uncover treatment opportunities that are often difficult to identify using conventional biomarker-focused approaches.

Clinical utility analysis of a computational reasoning system on large-scale tumor genomic data
Authors: Dóra Lakatos PhD, Robert Doczi, PhD, Mária Kocsis-Steinbach, Kalmar Gabor, Anna Dirner, Enikő Kispéter, Dóra Görög-Tihanyi, Barbara Vodicska, PhD, William T Beck, Istvan Petak MD, PhD

📍 Abstract 1625 | Poster Board 543
Track: Care Delivery / Models of Care (Hall A)
May 30, 2026, 9:00 - 12:00 PM CDT
Full abstract: https://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17086?presentation=263141
Breakdown of the results here: https://www.genomate.health/publication/genomate-clinical-utility-analysis-msk-chord-large-scale-tumor-genomic-data